Anavex Life Sciences Corp. (AVXL)’s Financial Results Comparing With Puma Biotechnology Inc. (NASDAQ:PBYI)

This is therefore a comparing of the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation in Anavex Life Sciences Corp. (NASDAQ:AVXL) and Puma Biotechnology Inc. (NASDAQ:PBYI). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anavex Life Sciences Corp. 3 0.00 47.30M -0.52 0.00
Puma Biotechnology Inc. 11 -0.02 30.91M -2.61 0.00

Table 1 highlights Anavex Life Sciences Corp. and Puma Biotechnology Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 has Anavex Life Sciences Corp. and Puma Biotechnology Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Anavex Life Sciences Corp. 1,589,488,540.90% -127.1% -102.3%
Puma Biotechnology Inc. 279,728,506.79% -245.2% -37.9%

Risk and Volatility

Anavex Life Sciences Corp.’s 2.23 beta indicates that its volatility is 123.00% more volatile than that of Standard & Poor’s 500. Puma Biotechnology Inc.’s 69.00% more volatile than Standard & Poor’s 500 volatility due to the stock’s 1.69 beta.


Anavex Life Sciences Corp. has a Current Ratio of 3.2 and a Quick Ratio of 3.2. Competitively, Puma Biotechnology Inc.’s Current Ratio is 2.5 and has 2.5 Quick Ratio. Anavex Life Sciences Corp.’s better ability to pay short and long-term obligations than Puma Biotechnology Inc.

Analyst Ratings

Anavex Life Sciences Corp. and Puma Biotechnology Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Anavex Life Sciences Corp. 0 0 2 3.00
Puma Biotechnology Inc. 0 0 0 0.00

Anavex Life Sciences Corp.’s upside potential currently stands at 323.45% and an $13 average target price.

Insider & Institutional Ownership

Roughly 14.2% of Anavex Life Sciences Corp. shares are owned by institutional investors while 99.8% of Puma Biotechnology Inc. are owned by institutional investors. Anavex Life Sciences Corp.’s share owned by insiders are 5.43%. Insiders Competitively, owned 11.4% of Puma Biotechnology Inc. shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Anavex Life Sciences Corp. -3.03% -33.33% -16.34% 37.63% -11.11% 64.1%
Puma Biotechnology Inc. -0.41% -24.61% -69.24% -64.26% -79.98% -52.58%

For the past year Anavex Life Sciences Corp. had bullish trend while Puma Biotechnology Inc. had bearish trend.


On 9 of the 11 factors Anavex Life Sciences Corp. beats Puma Biotechnology Inc.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of AlzheimerÂ’s disease, other central nervous system diseases, pain, and various cancers. The companyÂ’s lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of AlzheimerÂ’s disease; and preclinical stage to treat ParkinsonÂ’s disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat AlzheimerÂ’s disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.